{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-011443","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.812461+00:00","generated_at":"2026-06-17T07:55:12.387985+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Viking Therapeutics prices $250M public offering of 17.2M shares at $14.50","bullets":["Gross proceeds ~$250M from 17.2M shares at $14.50; underwriters have 30-day option for 2.6M additional shares.","Net proceeds to fund development programs VK2809, VK2735, VK0214 and for general R&D and working capital.","Lead bookrunners: William Blair and Raymond James; co-managers: BTIG, Oppenheimer, H.C. Wainwright, Maxim, Roth, Laidlaw.","Offering expected to close on April 3, 2023, subject to customary closing conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-011443","json":"https://secwatch.observer/filing/0000950170-23-011443.json","markdown":"https://secwatch.observer/filing/0000950170-23-011443.md","text":"https://secwatch.observer/filing/0000950170-23-011443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/0000950170-23-011443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/vktx-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:55:12.387985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc7c3e89ce3bfa59bfbc473a37889a4c3f88eda6","claim":"Viking Therapeutics, Inc. entered into Underwriting Agreement with William Blair & Company, L.L.C., as representative of the several underwriters valued at approximately $250.0 million (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 17,242,000 shares of the Company’s common stock (“Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/0000950170-23-011443-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"William Blair & Company, L.L.C., as representative of the several underwriters"},{"label":"Value","value":"approximately $250.0 million"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}